Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Andre

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative GroupJean-Marc Tourani, Christian Pfister, Nicole Tubiana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setAimery de Gramont, Joleen Hubbard, Qian Shi, et al.
European Urology Oncology|January 25, 2024
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)Bertrand F Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2024
Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patientsRémy Barbe, Younes Belkouchi, Yves Menu, et al.
JNCI Cancer Spectrum|April 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD databaseHideaki Bando, Yuriko Takeda, Toshihiro Misumi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints DatabaseWinson Y Cheung, Lindsay A Renfro, David Kerr, et al.
The Lancet. Oncology|April 15, 2022
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 studyLuis A Diaz, Kai-Keen Shiu, Tae-Won Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trialPascal Hammel, Portales Fabienne, Laurent Mineur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2020
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]Pascal Hammel, Fabienne Portales, Laurent Mineur, et al.
Journal of the National Cancer Institute|September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer TrialsJun Yin, Mohamed E Salem, Jesse G Dixon, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative GroupJean-Marc Tourani, Christian Pfister, Nicole Tubiana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setAimery de Gramont, Joleen Hubbard, Qian Shi, et al.
European Urology Oncology|January 25, 2024
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)Bertrand F Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2024
Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patientsRémy Barbe, Younes Belkouchi, Yves Menu, et al.
JNCI Cancer Spectrum|April 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD databaseHideaki Bando, Yuriko Takeda, Toshihiro Misumi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints DatabaseWinson Y Cheung, Lindsay A Renfro, David Kerr, et al.
The Lancet. Oncology|April 15, 2022
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 studyLuis A Diaz, Kai-Keen Shiu, Tae-Won Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trialPascal Hammel, Portales Fabienne, Laurent Mineur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2020
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]Pascal Hammel, Fabienne Portales, Laurent Mineur, et al.
Journal of the National Cancer Institute|September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer TrialsJun Yin, Mohamed E Salem, Jesse G Dixon, et al.
Pageof 6